Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
Nvidia Eyes $2.5 Billion Investment in Thinking Machines Lab 
Adobe Names Anil Chakravarthy CEO as AI Push Accelerates 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
SpaceX Turbine Push Unlikely to Threaten Howmet, Bernstein Says 
Anthropic Nears $15 Billion Credit Deal Ahead of IPO 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
Xiaomi Shares Jump on Europe EV Expansion Plan 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
Volkswagen Approves 50,000 More Job Cuts in Major Restructuring 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
Add as a preferred source on Google
WESTLAKE VILLAGE, Calif., Feb. 23, 2018 -- MannKind Corporation (Nasdaq:MNKD) will release its 2017 fourth quarter and full year financial results on Tuesday, February 27, 2018 and its management will host a conference call to discuss the financial results and other Company developments at 5:00 PM (Eastern Time) on February 27, 2018.
Presenting from the Company will be its Chief Executive Officer, Michael Castagna, Chief Financial Officer, Steven Binder, Chief Commercial Officer, Pat McCauley and Chief Medical Officer, David Kendall.
To participate in the live call by telephone, please dial (888) 771-4371 or (847) 585-4405 and use the participant passcode: 46307898. Those interested in listening to the conference call live via the Internet may do so by visiting the Company's website at www.mannkindcorp.com.
A telephone replay of the call will be accessible for approximately 14 days following completion of the call by dialing (888) 843-7419 or (630) 652-3042 and use the participant passcode: 4630 7898#. A replay will also be available on MannKind's website for 14 days.
ABOUT MANNKIND CORPORATION
MannKind Corporation (NASDAQ:MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. MannKind is currently commercializing Afrezza® (insulin human) inhalation powder, the Company's first FDA-approved product and the only inhaled rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut. The Company also employs field sales and medical representatives across the U.S. For further information, visit www.mannkindcorp.com.
Company Contact:
Rose Alinaya
SVP, Investor Relations
818-661-5000
[email protected]
